Carlsmed, Inc. (NASDAQ:CARL) Stock Has Average Price Target of $19.50 According to Analysts

Carlsmed, Inc. (NASDAQ:CARL) has earned a consensus recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $19.50.

Several equities analysts have weighed in on CARL shares. Weiss Ratings upgraded Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 11th. BTIG Research boosted their price target on Carlsmed from $23.00 to $24.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Truist Financial upped their price target on Carlsmed from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a report on Saturday, August 15th.

Carlsmed Stock Down 4.1%

Carlsmed stock opened at $14.40 on Wednesday. The company has a market capitalization of $393.12 million, a P/E ratio of -10.07 and a beta of 1.97. The firm’s fifty day simple moving average is $14.98 and its 200-day simple moving average is $12.46. The company has a current ratio of 8.84, a quick ratio of 8.66 and a debt-to-equity ratio of 0.18. Carlsmed has a 1-year low of $8.50 and a 1-year high of $17.23.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. The firm had revenue of $18.94 million during the quarter. Carlsmed had a negative net margin of 57.42% and a negative return on equity of 38.06%. Sell-side analysts forecast that Carlsmed will post -1.50 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carlsmed

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Jupiter Topco LLC bought a new position in shares of Carlsmed in the second quarter valued at approximately $12,992,000. Janus Henderson Group PLC boosted its holdings in shares of Carlsmed by 7.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after buying an additional 86,834 shares during the period. Parkman Healthcare Partners LLC bought a new stake in shares of Carlsmed during the 2nd quarter worth $6,200,000. BlackRock Inc. acquired a new position in Carlsmed in the 2nd quarter valued at $5,528,000. Finally, KCM Capital Inc acquired a new position in Carlsmed in the 1st quarter valued at $1,810,000.

About Carlsmed

Carlsmed, Inc is a medical technology company focused on personalized solutions for spine surgery. The company combines patient-specific planning, advanced imaging, software and additive manufacturing to develop implants designed to address the anatomical needs of individual patients.

Its products include the aprevo® patient-specific interbody implant system, which is designed for use in spinal fusion procedures. Carlsmed’s technology is intended to support surgeons in planning procedures and selecting or creating implants that may help restore spinal alignment and improve surgical precision.

Carlsmed serves the spine-care market through relationships with spine surgeons, hospitals and other healthcare providers.